SCHEMBL19973476

SCHEMBL19973476

COc1cc(NC(=O)c2ccc(F)c3c2OCC[C@@H]3NC(=O)O)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.43
NPC1 O15118 9/20 0.42
RAB9A P51151 8/20 0.42
MAPT P10636 7/20 0.42
TP53 P04637 4/20 0.41
TSHR P16473 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
STAT1 P42224 1/20 0.40
CPT2 P23786 2/20 0.39
CPT1A P50416 2/20 0.39
CPT1B Q92523 2/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CACNA1B Q00975 1/20 0.38
APBA1 Q02410 1/20 0.38
TOP2A P11388 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973477 1.00 GRM4 (0.43) GRM4NPC1RAB9AMAPTTP53
SCHEMBL21189285 0.92 GRM4 (0.43) GRM4NPC1RAB9AMAPTTP53
SCHEMBL19973442 0.89 HTR2B (0.40) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL19973441 0.89 HTR2B (0.40) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL19973898 0.89 MAOB (0.44) NPC1RAB9AMAPTTP53TSHR
SCHEMBL19973640 0.89 MAOB (0.44) NPC1RAB9AMAPTTP53TSHR
SCHEMBL19973639 0.89 MAOB (0.44) NPC1RAB9AMAPTTP53TSHR
SCHEMBL19973456 0.86 KMT2A (0.46) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL19973410 0.86 KMT2A (0.46) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL19973411 0.86 KMT2A (0.46) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS GRM4 3439/4885NPC1 983/4885RAB9A 1393/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS GRM4 3439/4885NPC1 983/4885RAB9A 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.